George Dangas, MD
Interventional Cardiology · New York, NYNPI 1124105002
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $190,716 of the $263,035 with a category attached, or 72.5%. Daiichi Sankyo Inc. accounts for 81.9% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $94,436 and has fallen 74.8% since, to $23,816 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $1839.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$215K
- Bayer$23K
- Medtronic$11K
- Daiichi Sankyo Company LTD$5K
- Edwards Lifesciences$2K
- Philips North America LLC$2K
- plus $5K from 17 others
Across 190 payments — averaging $12,083 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$2.2M
- Daiichi Sankyo Inc.$51K
- Medtronic$18K
- Biotronik Inc.$18K
- Pfizer$15K
What the payments were for
- Consulting fees$190,71673%
- Speaking & faculty fees$9,4004%
- Grants$2,4041%
- Travel & lodging$55,57521%
- Food & beverage$4,9402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 34 | $215,389 |
| Bayer | 13 | $23,220 |
| Medtronic(2 entities) | 5 | $10,758 |
| Daiichi Sankyo Company LTD | 3 | $4,793 |
| Edwards Lifesciences | 15 | $2,303 |
| Philips North America LLC | 3 | $1,942 |
| Abiomed | 15 | $1,706 |
| Abbott | 25 | $1,390 |
| Penumbra, Inc. | 6 | $338 |
| Shockwave Medical, Inc | 1 | $220 |
| Boston Scientific | 1 | $150 |
| Teleflex LLC | 1 | $139 |
| Cardiovascular Systems Inc. | 1 | $125 |
| Scpharmaceuticals Inc. | 1 | $120 |
| Novartis | 3 | $85 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $84 |
| Amgen | 4 | $80 |
| Cardiva Medical, Inc. | 2 | $63 |
| Chiesi USA, Inc. | 2 | $37 |
| Cook Medical LLC | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Acist Medical Systems, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Savaysa$80,684
- XARELTO$23,220
- CoreValve Evolut$8,000
- EVOQUE$1,862
- Impella$1,475
- Spectranetics Undiv$1,400
- Mitra Clip system$413
- (9520) IGT Devices Undivided$400
- Indigo System$235
- Vascular Lithotripsy$220
- IN.PACT Admiral$208
- DRAGONFLY OPSTAR$176
- MitraClip$159
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
- MOMENTUM$150
- Avalus$146
- Turbo Elite$142
- MANTA Vascular Closure Device$139
- Coronary Orbital Atherectomy System$125
- FUROSCIX$120
How this compares
$263,035 in reported general payments places this provider in the 95th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 78 | $97,559 |
| JardianceEmpagliflozin | 71 | $87,874 |
| Repatha SureclickEvolocumab | 61 | $36,852 |
| BrilintaTicagrelor | 35 | $30,859 |
| EntrestoSacubitril/Valsartan | 23 | $29,577 |
| XareltoRivaroxaban | 21 | $26,851 |
| Praluent PenAlirocumab | 16 | $11,644 |
| Ezetimibe | 180 | $6,070 |
| Rosuvastatin Calcium | 225 | $2,813 |
| Metoprolol Succinate | 225 | $2,775 |
| Bisoprolol Fumarate | 94 | $2,522 |
| Amiodarone Hcl | 25 | $2,224 |
| Amlodipine Besylate | 324 | $1,944 |
| Atorvastatin Calcium | 141 | $1,535 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 62 | $1,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $85 | $29,57723 claims |
| Johnson & JohnsonXarelto | $24 | $26,85121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in New York
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Sripal BangaloreNew York$482K
- Ajay KirtaneNew York$462K
- Prakash KrishnanNew York$387K
- Jaikirshan KhatriNew York$307K
- Samin SharmaNew York$291K
- Torsten VahlNew York$280K
- Jeffrey MosesNew York$238K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.